Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Trial details
- Registry ID
- NCT02112656
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Placebo
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)NCT02112656 | Imunon | Phase 3 | Completed | 2020-04-27Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |